Related Experiment Video
Updated: Apr 30, 2026
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Post-exposure therapy of filovirus infections
Gary Wong1, Xiangguo Qiu2, Gene G Olinger3
1Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
Abstract:
Filovirus infections cause fatal hemorrhagic fever characterized by the initial onset of general symptoms before rapid progression to severe disease; the most virulent species can cause death to susceptible hosts within 10 days after the appearance of symptoms. Before the advent of monoclonal antibody (mAb) therapy, infection of nonhuman primates (NHPs) with the most virulent filovirus species was fatal if interventions were not administered within minutes. A novel nucleoside analogue, BCX4430, has since been shown to also demonstrate protective efficacy with a delayed treatment start. This review summarizes and evaluates the potential of current experimental candidates for treating filovirus disease with regard to their feasibility and use in the clinic, and assesses the most promising strategies towards the future development of a pan-filovirus medical countermeasure.
Insights
Experimental treatments show promise for filovirus hemorrhagic fever. Novel therapies, including nucleoside analogues and monoclonal antibodies, offer potential clinical applications for treating these deadly infections.
Area of Science:
- Virology
- Infectious Diseases
- Medical Countermeasures
Background:
- Filovirus infections cause severe, rapidly progressing hemorrhagic fever with high mortality rates.
- Historically, treatment for virulent filovirus species in nonhuman primates (NHPs) required immediate intervention.
- Emerging therapies like monoclonal antibodies (mAbs) and nucleoside analogues offer new treatment possibilities.
Purpose of the Study:
- To review and evaluate current experimental filovirus disease treatments.
- To assess the clinical feasibility of these novel therapeutic candidates.
- To identify promising strategies for developing a pan-filovirus medical countermeasure.
Main Methods:
- Literature review of experimental filovirus treatments.
- Evaluation of therapeutic efficacy and treatment window.
- Assessment of clinical applicability and development strategies.
Main Results:
- Monoclonal antibody (mAb) therapy has demonstrated protective efficacy.
- A novel nucleoside analogue, BCX4430, shows protective effects even with delayed treatment.
- Several experimental candidates are being evaluated for clinical use.
Conclusions:
- Current experimental treatments, including mAbs and nucleoside analogues, show significant potential for treating filovirus infections.
- BCX4430 represents a promising therapeutic option with a delayed treatment window.
- Further development is needed to establish effective pan-filovirus medical countermeasures for clinical application.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:26Pharmaceutical Poisoning: Treatment Strategies